Immune ablation and stem-cell therapy in autoimmune disease: Experimental basis for autologous stem-cell transplantation
AUTOR(ES)
Bekkum, Dirk W van
FONTE
BioMed Central
RESUMO
Treatment of rats suffering from florid chronic progressive systemic arthritis or from chronic remitting/relapsing encephalomyelitis with autologous bone marrow transplantation (BMT) is highly effective. This finding was unexpected as the genotype of the bone marrow largely determines the susceptibility of both spontaneous and induced autoimmune diseases in rodents. The success of autologous stem-cell transplantation depends on the completeness of eradication of the effectors of autoimmune disease, in other words activated and memory T lymphocytes. The reviewed experimental data, when translated to the clinic, indicate that the patients should be subjected to a conditioning regimen that induces maximal lymphoablation and that the autologous transplant has to be T-cell depleted.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=130010Documentos Relacionados
- Immune ablation and stem-cell therapy in autoimmune disease: Introduction
- Immune ablation and stem-cell therapy in autoimmune disease: Immunological reconstitution after high-dose immunosuppression and haematopoietic stem-cell transplantation
- Immune ablation and stem-cell therapy in autoimmune disease: Clinical experience
- Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells
- Stem-cell therapy for hearing loss: are we there yet?
